ARWR
Arrowhead Pharmaceuticals Inc
61.50$
-0.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -156.9% | -3,318.5% | – | – | -581.7% | -5,850.9% | 84.8% | -557.2% | 8.0% | 5.1% | 114.5% | -235.8% | -8.8% | |
| 24.0% | 120.1% | – | – | 21.3% | 209.4% | 1.1% | 22.4% | 2.5% | 2.4% | 8.6% | 8.8% | 3.9% | |
| 112.9% | 554.6% | – | – | 82.6% | 608.4% | 3.0% | 47.0% | 7.4% | 7.3% | 22.8% | 19.6% | 10.5% | |
| 131.2% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 369.3% | -306.2% | – | – | 33.7% | -297.6% | 8.4% | -64.7% | -15.0% | -23.4% | 269.8% | -60.5% | 8.0% | |
| 397.0% | 1,933.4% | – | – | 103.0% | 300.6% | 1.0% | 8.5% | 2.9% | 0.8% | 3.5% | 5.1% | 2.4% | |
| 189.5% | 1,825.9% | – | – | -945.0% | 3,076.4% | -77.4% | 509.2% | 28.3% | -9.0% | -1,212.8% | 58.0% | -119.8% | |
| – | – | – | – | – | – | – | – | – | – | 56.3% | 51.1% | – | |
| – | – | – | – | – | 0.0% | -27.9% | -180.1% | 4.0% | -25.3% | 1,101.4% | -44.4% | 107.9% | |
| 0.9% | 7.5% | – | – | 1,649.5% | 825.4% | 17.0% | -153.7% | 1.4% | -5.6% | 1,079.1% | -0.6% | 117.1% | |
| 34.5% | -1,483.4% | – | – | 141.1% | -1,951.8% | 24.3% | -201.4% | 37.7% | -9.4% | -17.8% | -177.7% | -11.2% | |
| -553.9% | -5,251.9% | – | – | -684.7% | -6,151.5% | 83.8% | -565.7% | 5.1% | 4.3% | 111.0% | -241.0% | -11.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.